Sanofi agreed to acquire Dren Bio's DR-0201, a targeted bispecific myeloid cell engager for deep B-cell depletion, for $600M upfront plus $1.3B in milestones. Broadens Sanofi's immunology pipeline; DR-0201 is in Phase 1 for autoimmune diseases. Completed May 27, 2025.